Inhibitory effects of statins on human monocarboxylate transporter 4

International Journal of Pharmaceutics

Volumn 317, Issue 1, 2006, Pages 19-25

  Kobayashi, Masaki ^a   Otsuka, Yukio ^a   Itagaki, Shirou ^a   Hirano, Takeshi ^a   Iseki, Ken ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

HMG CoA reductase inhibitor; Monocarbocarboxylate transporter 4; Side effect; Transport

Indexed keywords

ATORVASTATIN; CD147 ANTIGEN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACTIC ACID; MEVINOLIN; MONOCARBOXYLATE TRANSPORTER; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CELL LINE; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPOPHILICITY; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TOXICITY TESTING; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD147; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LACTIC ACID; LLC-PK1 CELLS; LOVASTATIN; MONOCARBOXYLIC ACID TRANSPORTERS; MUSCLE PROTEINS; PYRIDINES; PYRROLES; SIMVASTATIN; SWINE; TRANSFECTION;

EID: 33745000275     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.02.043     Document Type: Article

References (22)

1. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., and Gotto Jr. A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
2. Evans M., and Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?. Drug Saf. 25 (2002) 649-663
3. Halestrap A.P., and Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch. 447 (2004) 619-628
4. Havel R.J., and Rapaport E. Management of primary hyperlipidemia. New Engl. J. Med. 332 (1995) 1491-1498
5. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol. Lett. 128 (2002) 159-168
6. Hosoya K., Kondo T., Tomi M., Takanaga H., Ohtsuki S., and Terasaki T. MCT1-mediated transport of l-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm. Res. 18 (2001) 1669-1676
7. Jeong D., Kim T.S., Lee J.W., Kim K.T., Kim H.J., Kim I.H., and Kim I.Y. Blocking of acidosis-mediated apoptosis by a reduction of lactate dehydrogenase activity through antisense mRNA expression. Biochem. Biophys. Res. Commun. 289 (2001) 1141-1149
8. Jukema J.W., Bruschke A.V., van Boven A.J., Reiber J.H., Bal E.T., Zwinderman A.H., Jansen H., Boerma G.J., van Rappard F.M., and Lie K.I. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91 (1995) 2528-2540
9. Kubota T., Fujisaki K., Itoh Y., Yano T., Sendo T., and Oishi R. Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors. Biochem. Pharmacol. 67 (2004) 2175-2186
10. Kobayashi M., Fujita I., Itagaki S., Hirano T., and Iseki K. Transport mechanism for l-lactic acid in human myocytes using human prototypic embryonal rhabdomyosarcoma cell line (RD cells). Biol. Pharm. Bull. 28 (2005) 1197-1201
11. Kobayashi M., Itagaki S., Hirano T., and Iseki K. Mechanism of l-lactic acid transport in L6 skeletal muscle cells. Drug Metab. Pharmacokinet. 19 (2004) 363-368
12. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
13. Manning Fox J.E., Meredith D., and Halestrap A.P. Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle. J. Physiol. 529 (2000) 285-293
14. Matsuyama K., Nakagawa K., Nakai A., Konishi Y., Nishikata M., Tanaka H., and Uchida T. Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method. Biol. Pharm. Bull. 25 (2002) 346-350
15. Matzno S., Tazuya-Murayama K., Tanaka H., Yasuda S., Mishima M., Uchida T., Nakabayashi T., and Matsuyama K. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J. Pharm. Pharmacol. 55 (2003) 795-802
16. Nagasawa K., Muraki Y., Matsuda T., Ohnishi N., and Yokoyama T. Inhibitory effect of statins on fetal bovine serum-induced proliferation of rat cultured mesangial cells and correlation between their inhibitory effect and transport characteristics. J. Pharm. Sci. 89 (2000) 1594-1604
17. Nagasawa K., Nagai K., Ishimoto A., and Fujimoto S. Transport mechanism for lovastatin acid in bovine kidney NBL-1 cells: kinetic evidences imply involvement of monocarboxylate transporter 4. Int. J. Pharm. 262 (2003) 63-73
18. Takeda M., Noshiro R., Onozato M.L., Tojo A., Hasannejad H., Huang X.L., Narikawa S., and Endou H. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur. J. Pharmacol. 483 (2004) 133-138
19. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
20. Wilson M.C., Jackson V.N., Heddle C., Price N.T., Pilegaard H., Juel C., Bonen A., Montgomery I., Hutter O.F., and Halestrap A.P. Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3. J. Biol. Chem. 273 (1998) 15920-15926
21. Wu X., Whitfield L.R., and Stewart B.H. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm. Res. 17 (2000) 209-215
22. Zhang L., Gorset W., Washington C.B., Blaschke T.F., Kroetz D.L., and Giacomini K.M. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab. Dispos. 28 (2000) 329-334